US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

The Aaron's Company, Inc.

10.09

0.0000

Volume:- -

Turnover:- -

Market Cap:309.89M

PE:-7.25

High:10.09

Open:10.09

Low:10.09

Close:10.09

52wk High:11.90

52wk Low:6.62

Shares:30.71M

Float Shares:29.87M

Volume Ratio:- -

T/O Rate:- -

Dividend:0.50

Dividend Rate:4.96%

EPS(TTM):-1.3911

EPS(LYR):0.0917

ROE:-6.22%

ROA:2.18%

PB:0.47

PE(LYR):110.01

Loading ...

Overview Company News Filings

Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results

Press Release: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Press Release: Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update

Press Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results

Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update

Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®

Argenx Showcases Broad VYVGART and Pipeline Gains at AAN 2026 to Bolster Neuromuscular Leadership

Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

Alterity to Spotlight ATH434 MSA Data in Late-Breaker at AAN Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AAN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAN\",,,,,undefined,":{"symbol":"AAN","market":"US","secType":"STK","nameCN":"The Aaron's Company, Inc.","latestPrice":10.09,"timestamp":1783627200000,"preClose":10.09,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":29872074,"shares":30712772,"eps":-1.391109,"marketStatus":"Not Yet Opened","change":0,"latestTime":"07-09 16:00:00 EDT","open":10.09,"high":10.09,"low":10.09,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.391109,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785225600000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":10.09,"dividendRate":0.049554,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAN\",,,,,undefined,":{"symbol":"AAN","floatShares":29872074,"roa":"2.18%","roe":"-6.22%","lyrEps":0.091721,"shares":30712772,"dividePrice":0.5,"high":10.09,"amplitude":0,"preClose":10.09,"low":10.09,"week52Low":6.622,"pbRate":"0.47","psRate":"0.15","week52High":11.9,"institutionHeld":0.9259,"latestPrice":10.09,"eps":-1.391109,"divideRate":0.049554,"volume":0,"delay":0,"ttmEps":-1.391109,"open":10.09,"prevYearClose":10.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-10-04","symbol":"AAN","reason":null,"defaultRemindTime":1728048600000,"announcedDate":"2024-09-20","type":"delisting","dateTimestamp":1728014400000},{"date":"2024-09-13","symbol":"AAN","amount":0.125,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-13","defaultRemindTime":1726234200000,"name":"The Aaron's Company, Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-03","payableDate":"2024-09-13","currency":"USD","dateTimestamp":1726200000000,"payDate":"2024-10-03"},{"date":"2024-08-05","symbol":"AAN","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/06","expectedEps":0.03,"defaultRemindTime":1722888000000,"name":null,"time":"Post Market","dateTimestamp":1722830400000,"actualEps":null},{"date":"2024-06-14","symbol":"AAN","amount":0.125,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-06-14","defaultRemindTime":1718371800000,"name":"The Aaron's Company, Inc.","recordDate":"2024-07-03","payableDate":"2024-06-14","currency":"USD","dateTimestamp":1718337600000,"payDate":"2024-07-03"},{"date":"2024-05-06","symbol":"AAN","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/03","expectedEps":-0.08,"defaultRemindTime":1715025600000,"name":null,"time":"Post Market","dateTimestamp":1714968000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAN\",market:\"US\",,,undefined,":[{"executeDate":"2017-03-13","recordDate":null,"paymentDate":null,"value":0.0275,"currency":"USD"},{"executeDate":"2017-06-23","recordDate":null,"paymentDate":null,"value":0.0275,"currency":"USD"},{"executeDate":"2017-09-14","recordDate":null,"paymentDate":null,"value":0.0275,"currency":"USD"},{"executeDate":"2017-12-12","recordDate":null,"paymentDate":null,"value":0.03,"currency":"USD"},{"executeDate":"2018-03-22","recordDate":null,"paymentDate":null,"value":0.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":7,"updateTime":1720670400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAN","date":"2024-10-02","current":-7.253206,"percent":0.311436,"low":-226.61145,"twenty":-13.023365,"median":6.536302,"eighty":20.725985,"high":112.497555,"avg":-0.454661,"sd":44.674017,"marketCap":304670698},"quantilePoints":[{"date":"2021-07-30","current":9.001746,"twenty":-9.75604,"median":11.175949,"eighty":14.583366,"marketCap":943256951},{"date":"2021-08-06","current":8.621347,"twenty":-9.731195,"median":11.141484,"eighty":14.569104,"marketCap":903396422},{"date":"2021-08-13","current":9.117113,"twenty":-9.719216,"median":10.680732,"eighty":14.542881,"marketCap":955345800},{"date":"2021-08-20","current":8.764776,"twenty":-9.702358,"median":10.238148,"eighty":14.515087,"marketCap":918425802},{"date":"2021-08-27","current":8.602638,"twenty":-9.686386,"median":10.004734,"eighty":14.503803,"marketCap":901436068},{"date":"2021-09-03","current":8.371904,"twenty":-9.670858,"median":9.878227,"eighty":14.495035,"marketCap":877258370},{"date":"2021-09-10","current":8.178587,"twenty":-9.661985,"median":9.724994,"eighty":14.487674,"marketCap":857001379},{"date":"2021-09-17","current":8.396849,"twenty":-9.651781,"median":9.151412,"eighty":14.481233,"marketCap":879872175},{"date":"2021-09-24","current":8.580812,"twenty":-9.63226,"median":9.001746,"eighty":14.46099,"marketCap":899148988},{"date":"2021-10-01","current":8.761658,"twenty":-9.601647,"median":8.958094,"eighty":14.437068,"marketCap":918099076},{"date":"2021-10-08","current":8.714887,"twenty":-9.542197,"median":8.892615,"eighty":14.434307,"marketCap":913198191},{"date":"2021-10-15","current":8.56834,"twenty":-9.495613,"median":8.813105,"eighty":14.433387,"marketCap":897842086},{"date":"2021-10-22","current":9.447624,"twenty":-9.47343,"median":8.883261,"eighty":14.431087,"marketCap":989978719},{"date":"2021-10-29","current":7.629357,"twenty":-9.434388,"median":8.8209,"eighty":14.420506,"marketCap":736393147},{"date":"2021-11-05","current":8.350215,"twenty":-9.394459,"median":8.792838,"eighty":14.39847,"marketCap":805971123},{"date":"2021-11-12","current":8.568756,"twenty":-9.349649,"median":8.764776,"eighty":14.382391,"marketCap":827064898},{"date":"2021-11-19","current":8.239314,"twenty":-9.109187,"median":8.724241,"eighty":14.37404,"marketCap":795266819},{"date":"2021-11-26","current":7.847898,"twenty":-8.748937,"median":8.714887,"eighty":14.357938,"marketCap":757486922},{"date":"2021-12-03","current":7.440172,"twenty":-8.524445,"median":8.691502,"eighty":14.306872,"marketCap":718132864},{"date":"2021-12-10","current":7.94249,"twenty":-8.467214,"median":8.668117,"eighty":14.283409,"marketCap":766617064},{"date":"2021-12-17","current":7.844636,"twenty":-8.262243,"median":8.662471,"eighty":14.239703,"marketCap":757172090},{"date":"2021-12-23","current":7.988155,"twenty":-8.187709,"median":8.61667,"eighty":14.234182,"marketCap":771024719},{"date":"2021-12-31","current":8.040344,"twenty":-8.054612,"median":8.608874,"eighty":14.21348,"marketCap":776062038},{"date":"2022-01-07","current":7.74352,"twenty":-8.039083,"median":8.604197,"eighty":14.188176,"marketCap":747412283},{"date":"2022-01-14","current":7.489099,"twenty":-7.937042,"median":8.587048,"eighty":14.176675,"marketCap":722855351},{"date":"2022-01-21","current":6.954164,"twenty":-7.711664,"median":8.580812,"eighty":14.163793,"marketCap":671222826},{"date":"2022-01-28","current":6.771503,"twenty":-7.561264,"median":8.568548,"eighty":14.153212,"marketCap":653592207},{"date":"2022-02-04","current":6.774764,"twenty":-7.498708,"median":8.50598,"eighty":14.13849,"marketCap":653907040},{"date":"2022-02-11","current":6.800859,"twenty":-7.4783,"median":8.402672,"eighty":14.109507,"marketCap":656425699},{"date":"2022-02-18","current":6.85631,"twenty":-7.417075,"median":8.390613,"eighty":14.090805,"marketCap":661777851},{"date":"2022-02-25","current":6.0444,"twenty":-7.399772,"median":8.371904,"eighty":14.073473,"marketCap":664485049},{"date":"2022-03-04","current":6.303647,"twenty":-7.338104,"median":8.35837,"eighty":14.046019,"marketCap":692985107},{"date":"2022-03-11","current":6.154298,"twenty":-7.214323,"median":8.322016,"eighty":14.028536,"marketCap":676566596},{"date":"2022-03-18","current":6.531897,"twenty":-7.133134,"median":8.300596,"eighty":14.016575,"marketCap":718077550},{"date":"2022-03-25","current":6.358874,"twenty":-7.012459,"median":8.278364,"eighty":13.990352,"marketCap":699056405},{"date":"2022-04-01","current":5.853417,"twenty":-6.728961,"median":8.262316,"eighty":13.959988,"marketCap":643489564},{"date":"2022-04-08","current":6.111955,"twenty":-4.797768,"median":8.237829,"eighty":13.929624,"marketCap":671911684},{"date":"2022-04-14","current":6.210723,"twenty":-3.54381,"median":8.229529,"eighty":13.89558,"marketCap":682769573},{"date":"2022-04-22","current":5.94928,"twenty":-3.437831,"median":8.209791,"eighty":13.857395,"marketCap":654028103},{"date":"2022-04-29","current":6.626359,"twenty":-3.415191,"median":8.180601,"eighty":13.79395,"marketCap":630451705},{"date":"2022-05-06","current":6.539213,"twenty":-3.410303,"median":8.142587,"eighty":13.634075,"marketCap":622160328},{"date":"2022-05-13","current":6.452066,"twenty":-3.405158,"median":8.086009,"eighty":13.512696,"marketCap":613868951},{"date":"2022-05-20","current":5.864635,"twenty":-3.380718,"median":8.051782,"eighty":13.496451,"marketCap":557978932},{"date":"2022-05-27","current":6.077659,"twenty":-3.349589,"median":8.001202,"eighty":13.451527,"marketCap":578246741},{"date":"2022-06-03","current":5.961464,"twenty":-3.34573,"median":7.971846,"eighty":13.396862,"marketCap":567191572},{"date":"2022-06-10","current":5.796854,"twenty":-3.345215,"median":7.947382,"eighty":13.321166,"marketCap":551530083},{"date":"2022-06-17","current":5.060951,"twenty":-3.339813,"median":7.90661,"eighty":13.254413,"marketCap":481514015},{"date":"2022-06-24","current":5.222333,"twenty":-3.326435,"median":7.860945,"eighty":13.231199,"marketCap":496868416},{"date":"2022-07-01","current":4.760779,"twenty":-3.316144,"median":7.81528,"eighty":13.22259,"marketCap":452954829},{"date":"2022-07-08","current":4.947983,"twenty":-3.305854,"median":7.76146,"eighty":13.21226,"marketCap":470765934},{"date":"2022-07-15","current":4.734958,"twenty":-3.289903,"median":7.704378,"eighty":13.206235,"marketCap":450498125},{"date":"2022-07-22","current":5.167463,"twenty":-3.28553,"median":7.670129,"eighty":13.197004,"marketCap":491647920},{"date":"2022-07-29","current":7.051656,"twenty":-3.278069,"median":7.648928,"eighty":13.194912,"marketCap":400717386},{"date":"2022-08-05","current":7.214136,"twenty":-3.275239,"median":7.552705,"eighty":13.171694,"marketCap":409950505},{"date":"2022-08-12","current":7.907387,"twenty":-3.267779,"median":7.629357,"eighty":13.156156,"marketCap":449345149},{"date":"2022-08-19","current":7.598674,"twenty":-3.244368,"median":7.653821,"eighty":13.131529,"marketCap":431802221},{"date":"2022-08-26","current":6.932503,"twenty":-3.236907,"median":7.598674,"eighty":13.111469,"marketCap":393946432},{"date":"2022-09-02","current":6.428814,"twenty":-3.219927,"median":7.549929,"eighty":13.107841,"marketCap":365323761},{"date":"2022-09-09","current":6.640038,"twenty":-3.21118,"median":7.533133,"eighty":13.099134,"marketCap":377326816},{"date":"2022-09-16","current":6.612958,"twenty":-3.207321,"median":7.484937,"eighty":13.091152,"marketCap":375787963},{"date":"2022-09-23","current":5.8493,"twenty":-3.205263,"median":7.456481,"eighty":13.087524,"marketCap":332392302},{"date":"2022-09-30","current":5.26437,"twenty":-3.201919,"median":7.440172,"eighty":13.068659,"marketCap":299153071},{"date":"2022-10-07","current":5.145217,"twenty":-3.198832,"median":7.301545,"eighty":13.052696,"marketCap":292382117},{"date":"2022-10-14","current":4.798592,"twenty":-3.190085,"median":7.23794,"eighty":13.04544,"marketCap":272684795},{"date":"2022-10-21","current":4.717352,"twenty":-3.17645,"median":7.204836,"eighty":13.012404,"marketCap":268068236},{"date":"2022-10-28","current":18.856739,"twenty":-3.156126,"median":7.23794,"eighty":13.087524,"marketCap":317962337},{"date":"2022-11-04","current":17.72497,"twenty":-3.141719,"median":7.301545,"eighty":13.115097,"marketCap":298878441},{"date":"2022-11-11","current":20.882972,"twenty":-3.13786,"median":7.440172,"eighty":13.194912,"marketCap":352128668},{"date":"2022-11-18","current":20.171052,"twenty":-3.129627,"median":7.456481,"eighty":13.226034,"marketCap":340124281},{"date":"2022-11-25","current":21.138532,"twenty":-3.119851,"median":7.477233,"eighty":13.381747,"marketCap":356437935},{"date":"2022-12-02","current":22.945713,"twenty":-3.112391,"median":7.528241,"eighty":13.634075,"marketCap":386910608},{"date":"2022-12-09","current":21.412348,"twenty":-3.103901,"median":7.549929,"eighty":13.936064,"marketCap":361055006},{"date":"2022-12-16","current":21.722672,"twenty":-3.091295,"median":7.598674,"eighty":14.030377,"marketCap":366287688},{"date":"2022-12-23","current":20.755191,"twenty":-3.086664,"median":7.653821,"eighty":14.122388,"marketCap":349974034},{"date":"2022-12-30","current":21.813943,"twenty":-3.077344,"median":7.683177,"eighty":14.173455,"marketCap":367826712},{"date":"2023-01-06","current":23.821921,"twenty":-3.05859,"median":7.720687,"eighty":14.234182,"marketCap":401685237},{"date":"2023-01-13","current":26.194986,"twenty":-3.050427,"median":7.750322,"eighty":14.369899,"marketCap":441699859},{"date":"2023-01-20","current":25.884662,"twenty":-3.037365,"median":7.785923,"eighty":14.411305,"marketCap":436467178},{"date":"2023-01-27","current":26.158478,"twenty":-2.983948,"median":7.846267,"eighty":14.435227,"marketCap":441084249},{"date":"2023-02-03","current":28.239473,"twenty":-2.934484,"median":7.860945,"eighty":14.492274,"marketCap":476173994},{"date":"2023-02-10","current":26.724362,"twenty":-2.921987,"median":7.903348,"eighty":14.564964,"marketCap":450626197},{"date":"2023-02-17","current":26.92516,"twenty":-2.910286,"median":7.907387,"eighty":14.628911,"marketCap":454012050},{"date":"2023-02-24","current":25.793391,"twenty":-2.891238,"median":7.922919,"eighty":14.647007,"marketCap":434928154},{"date":"2023-03-03","current":-74.11349,"twenty":-2.922804,"median":7.915153,"eighty":14.672386,"marketCap":391319229},{"date":"2023-03-10","current":-64.718823,"twenty":-3.053692,"median":7.907387,"eighty":14.647007,"marketCap":341715383},{"date":"2023-03-17","current":-54.86022,"twenty":-3.100042,"median":7.890196,"eighty":14.635427,"marketCap":289661964},{"date":"2023-03-24","current":-55.522605,"twenty":-3.13786,"median":7.853226,"eighty":14.634482,"marketCap":293159356},{"date":"2023-03-31","current":-58.235436,"twenty":-3.190085,"median":7.835391,"eighty":14.630291,"marketCap":307483103},{"date":"2023-04-06","current":-57.512015,"twenty":-3.205778,"median":7.782661,"eighty":14.622931,"marketCap":303663437},{"date":"2023-04-14","current":-64.62566,"twenty":-3.237936,"median":7.74352,"eighty":14.604068,"marketCap":341223485},{"date":"2023-04-21","current":-62.214255,"twenty":-3.281671,"median":7.694593,"eighty":14.584286,"marketCap":328491265},{"date":"2023-04-28","current":-29.179552,"twenty":-3.322319,"median":7.658713,"eighty":14.573245,"marketCap":408922246},{"date":"2023-05-05","current":-26.224103,"twenty":-3.349589,"median":7.614015,"eighty":14.548861,"marketCap":367504573},{"date":"2023-05-12","current":-27.701827,"twenty":-3.415191,"median":7.555345,"eighty":14.520365,"marketCap":388213410},{"date":"2023-05-19","current":-28.650218,"twenty":-6.80039,"median":7.533133,"eighty":14.504046,"marketCap":401504155},{"date":"2023-05-26","current":-27.282771,"twenty":-7.358069,"median":7.484937,"eighty":14.497795,"marketCap":382340755},{"date":"2023-06-02","current":-27.018104,"twenty":-7.486286,"median":7.459743,"eighty":14.488594,"marketCap":378631709},{"date":"2023-06-09","current":-31.782113,"twenty":-8.018675,"median":7.446307,"eighty":14.483074,"marketCap":445394525},{"date":"2023-06-16","current":-30.017665,"twenty":-8.467214,"median":7.348842,"eighty":14.468351,"marketCap":420667556},{"date":"2023-06-23","current":-28.716385,"twenty":-9.312382,"median":7.241202,"eighty":14.438908,"marketCap":402431417},{"date":"2023-06-30","current":-31.605668,"twenty":-9.459233,"median":7.224968,"eighty":14.435227,"marketCap":442921828},{"date":"2023-07-07","current":-31.892391,"twenty":-9.591,"median":7.195537,"eighty":14.434307,"marketCap":446939961},{"date":"2023-07-14","current":-33.083393,"twenty":-9.670858,"median":7.136824,"eighty":14.432927,"marketCap":463630665},{"date":"2023-07-21","current":-34.340562,"twenty":-9.731195,"median":7.111232,"eighty":14.430627,"marketCap":481248630},{"date":"2023-07-28","current":-33.921505,"twenty":-9.803955,"median":7.051837,"eighty":14.415905,"marketCap":475375975},{"date":"2023-08-04","current":-188.365396,"twenty":-9.879821,"median":7.029992,"eighty":14.394353,"marketCap":405927428},{"date":"2023-08-11","current":-189.224858,"twenty":-9.963672,"median":6.998198,"eighty":14.380528,"marketCap":407779569},{"date":"2023-08-18","current":-177.90861,"twenty":-10.056396,"median":6.986782,"eighty":14.372659,"marketCap":383393054},{"date":"2023-08-25","current":-170.316697,"twenty":-10.152227,"median":6.952533,"eighty":14.334015,"marketCap":367032481},{"date":"2023-09-01","current":-172.895082,"twenty":-11.528064,"median":6.932503,"eighty":14.300431,"marketCap":372588902},{"date":"2023-09-08","current":-145.392302,"twenty":-12.623461,"median":6.905237,"eighty":14.272827,"marketCap":313320410},{"date":"2023-09-15","current":-149.25988,"twenty":-13.033575,"median":6.884571,"eighty":14.238323,"marketCap":321655042},{"date":"2023-09-22","current":-152.697728,"twenty":-13.168875,"median":6.85631,"eighty":14.225901,"marketCap":329063603},{"date":"2023-09-29","current":-152.41124,"twenty":-13.297434,"median":6.830215,"eighty":14.203358,"marketCap":328446223},{"date":"2023-10-06","current":-140.665261,"twenty":-13.435141,"median":6.802519,"eighty":14.183576,"marketCap":303133638},{"date":"2023-10-13","current":-136.797683,"twenty":-13.525181,"median":6.773134,"eighty":14.170234,"marketCap":294799007},{"date":"2023-10-20","current":-133.646323,"twenty":-13.584405,"median":6.745664,"eighty":14.158733,"marketCap":288007825},{"date":"2023-10-27","current":23.778109,"twenty":-13.598368,"median":6.745664,"eighty":14.167014,"marketCap":221707087},{"date":"2023-11-03","current":23.680524,"twenty":-13.577664,"median":6.774764,"eighty":14.236942,"marketCap":220797209},{"date":"2023-11-10","current":22.346868,"twenty":-13.547812,"median":6.803199,"eighty":14.372659,"marketCap":208362201},{"date":"2023-11-17","current":27.909189,"twenty":-13.52807,"median":6.836739,"eighty":14.430627,"marketCap":260225282},{"date":"2023-11-24","current":28.917563,"twenty":-13.525181,"median":6.85631,"eighty":14.437068,"marketCap":269627361},{"date":"2023-12-01","current":28.657338,"twenty":-13.505446,"median":6.884571,"eighty":14.497795,"marketCap":267201018},{"date":"2023-12-08","current":34.02449,"twenty":-13.470998,"median":6.905237,"eighty":14.573245,"marketCap":317244342},{"date":"2023-12-15","current":38.123042,"twenty":-13.460384,"median":6.940627,"eighty":14.631672,"marketCap":355459243},{"date":"2023-12-22","current":36.333991,"twenty":-13.435141,"median":6.954164,"eighty":14.677371,"marketCap":338778135},{"date":"2023-12-29","current":36.333991,"twenty":-13.404807,"median":6.970474,"eighty":14.704211,"marketCap":338778135},{"date":"2024-01-05","current":36.952027,"twenty":-13.397585,"median":6.991083,"eighty":14.719535,"marketCap":344540700},{"date":"2024-01-12","current":35.423202,"twenty":-13.386992,"median":7.016542,"eighty":14.743005,"marketCap":330285935},{"date":"2024-01-19","current":33.308869,"twenty":-13.35425,"median":7.040824,"eighty":14.762852,"marketCap":310571898},{"date":"2024-01-26","current":34.870223,"twenty":-13.297434,"median":7.052018,"eighty":14.7972,"marketCap":325129956},{"date":"2024-02-02","current":33.66668,"twenty":-13.239655,"median":7.119356,"eighty":14.868142,"marketCap":313908120},{"date":"2024-02-09","current":33.991961,"twenty":-13.181312,"median":7.140086,"eighty":14.902766,"marketCap":316941049},{"date":"2024-02-16","current":35.228033,"twenty":-13.176456,"median":7.204836,"eighty":15.530992,"marketCap":328466178},{"date":"2024-02-23","current":33.146228,"twenty":-13.171283,"median":7.231454,"eighty":16.007704,"marketCap":309055434},{"date":"2024-03-01","current":83.351439,"twenty":-13.159245,"median":7.254249,"eighty":16.944381,"marketCap":235301113},{"date":"2024-03-08","current":77.221075,"twenty":-13.139022,"median":7.397562,"eighty":17.504731,"marketCap":217995096},{"date":"2024-03-15","current":74.74742,"twenty":-13.092318,"median":7.453219,"eighty":17.739361,"marketCap":211011966},{"date":"2024-03-22","current":81.364368,"twenty":-13.05428,"median":7.477233,"eighty":17.972015,"marketCap":229691610},{"date":"2024-03-28","current":80.387995,"twenty":-12.971462,"median":7.50867,"eighty":18.290855,"marketCap":226935310},{"date":"2024-04-05","current":78.760708,"twenty":-12.865396,"median":7.544513,"eighty":18.783722,"marketCap":222341478},{"date":"2024-04-12","current":77.458878,"twenty":-12.701825,"median":7.583029,"eighty":19.185317,"marketCap":218666412},{"date":"2024-04-19","current":79.303137,"twenty":-12.659492,"median":7.648928,"eighty":20.171052,"marketCap":223872755},{"date":"2024-04-26","current":79.411623,"twenty":-12.569414,"median":7.683177,"eighty":20.718683,"marketCap":224179011},{"date":"2024-05-03","current":73.661874,"twenty":-12.562192,"median":7.736996,"eighty":20.882972,"marketCap":207947470},{"date":"2024-05-10","current":-9.41993,"twenty":-12.422559,"median":7.694593,"eighty":20.882972,"marketCap":227547821},{"date":"2024-05-17","current":-9.55939,"twenty":-10.931734,"median":7.658713,"eighty":20.755191,"marketCap":230916631},{"date":"2024-05-24","current":-9.064939,"twenty":-10.752052,"median":7.614015,"eighty":20.736937,"marketCap":218972668},{"date":"2024-05-31","current":-9.77492,"twenty":-10.40245,"median":7.561364,"eighty":20.736937,"marketCap":236122975},{"date":"2024-06-07","current":-10.751145,"twenty":-10.751145,"median":7.538026,"eighty":20.722334,"marketCap":259704647},{"date":"2024-06-14","current":-9.812955,"twenty":-10.735931,"median":7.489099,"eighty":20.685825,"marketCap":237041741},{"date":"2024-06-21","current":-13.023365,"twenty":-10.751689,"median":7.469528,"eighty":20.598203,"marketCap":314592404},{"date":"2024-06-28","current":-12.984217,"twenty":-10.787988,"median":7.459743,"eighty":20.532488,"marketCap":313646735},{"date":"2024-07-05","current":-13.036414,"twenty":-12.56797,"median":7.440172,"eighty":20.433914,"marketCap":314907627},{"date":"2024-07-12","current":-12.997266,"twenty":-12.950249,"median":7.23794,"eighty":20.433914,"marketCap":313961958},{"date":"2024-07-15","current":-13.036414,"twenty":-12.981666,"median":7.224968,"eighty":20.433914,"marketCap":314907627},{"date":"2024-08-02","current":-13.127761,"twenty":-13.007706,"median":7.086518,"eighty":20.725985,"marketCap":317114187},{"date":"2024-08-09","current":-7.228062,"twenty":-13.023365,"median":7.029992,"eighty":20.725985,"marketCap":307741975},{"date":"2024-08-16","current":-7.271344,"twenty":-13.023365,"median":6.970474,"eighty":20.725985,"marketCap":309584741},{"date":"2024-08-23","current":-7.26413,"twenty":-13.023365,"median":6.9205,"eighty":20.725985,"marketCap":309277614},{"date":"2024-08-30","current":-7.278558,"twenty":-13.023365,"median":6.879843,"eighty":20.725985,"marketCap":309891869},{"date":"2024-09-06","current":-7.206421,"twenty":-13.023365,"median":6.830215,"eighty":20.725985,"marketCap":306820592},{"date":"2024-09-13","current":-7.292985,"twenty":-13.023365,"median":6.773134,"eighty":20.725985,"marketCap":310506124},{"date":"2024-09-20","current":-7.242489,"twenty":-13.023365,"median":6.654179,"eighty":20.725985,"marketCap":308356230},{"date":"2024-09-27","current":-7.235276,"twenty":-13.023365,"median":6.602126,"eighty":20.725985,"marketCap":308049103},{"date":"2024-10-02","current":-7.155926,"twenty":-13.023365,"median":6.536302,"eighty":20.725985,"marketCap":304670698}],"updateTime":1785215194478},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635711352","title":"Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635711352","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635711352?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:05","pubTimestamp":1778756700,"startTime":"0","endTime":"0","summary":"Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV study presented today at ASGCT 2026 Annual Meeting along with initial re","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294776/0/en/Cabaletta-Bio-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DM","BK4139","AAN","BK4546","BK4178","CABA","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635242055","title":"Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242055","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242055?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:02","pubTimestamp":1778616120,"startTime":"0","endTime":"0","summary":"Positive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndrome (SPS); rolling BLA submission initiated Miv-cel pivotal trial primary analysis results in SPS de","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3293353/0/en/Kyverna-Therapeutics-Announces-Initiation-of-Rolling-SPS-BLA-Submission-and-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0963586101.USD","BK4178","LU0267386448.USD","BK4006","CMC","BK4139","LU2065731478.USD","LU2746668461.USD","IE00B19Z4B17.USD","IE00B1BXHZ80.USD","LU0882574139.USD","BK4230","IE00BFXG1179.USD","LD","CRS","AAN","IE00BKVL7J92.USD","LU0170899867.USD","IE00B66KJ199.SGD","IE0031619046.USD","LU2237443622.USD","LU0149725797.USD","LU2237443895.HKD","IE00B7SZL793.SGD","KYTX","LU0971096721.USD","BK4588","LU2237443382.USD","IE00BHPRN162.USD","HCP","CSF","LU2237443465.HKD","LU2237443549.SGD","BK4023","BK4022","CAR","LU2237443978.SGD","IE00BZ1G4Q59.USD","LU2746668974.SGD","BK4187","LU1363072403.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633410981","title":"Press Release: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633410981","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633410981?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155200,"startTime":"0","endTime":"0","summary":"FDA accepted the new drug application  for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and SCN8A developmental and epileptic encephalopathies  with a PDUFA target action date of September 27, 2026. EMBRAVE Part A study results showed elsunersen treatment led to a 77% placebo-adjusted reduction in monthly seizures and demonstrated disease-modifying improvements in patients with early-seizure onset SCN2A-DEE. Topline results from the POWER1 study of vormatrigine in focal onset seizures expected in Q2 2026. Recruiting completed for relutrigine EMERALD study in broad DEEs, with topline results expected in Q4 2026. Cash and investments of approximately $1.4 billion as of March 31, 2026 maintains runway into 2028. BOSTON, May 07, 2026  -- Praxis Precision Medicines, Inc. , a fully integrated, leading central nervous system  precision neuroscience biopharmaceutical company, today provided a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4144","IE0009355771.USD","LU0109394709.USD","AAN","IE00BJJMRZ35.SGD","ET","PRAX","IE0002141913.USD","03160","IE00B4R5TH58.HKD","BK4099","BK4588","BK4200","ASO","BK4178","BK4561","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4604","BK4139","BK4585","IE00BFTCPJ56.SGD","BK4555","BK4590","LU0320765992.SGD","LU0889565916.HKD","TM","CNS","BK4581","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633149460","title":"Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633149460","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633149460?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:30","pubTimestamp":1778153400,"startTime":"0","endTime":"0","summary":"SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851 init","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289862/0/en/Lexicon-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Provides-Clinical-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4588","BK4599","BK4139","IE00BZ1G4Q59.USD","LU1093756168.USD","LU0154236417.USD","IE00BKVL7J92.USD","NVOH","BK4178","LXRX","BK4532","NVOX","BK4585","AAN","NVO","LU1093756325.SGD","HCM","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633814551","title":"Press Release: Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633814551","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633814551?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Phase 2a follow-up period data for RAP-219 in focal onset seizures  demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12. RAP-219 Phase 2 trial in bipolar mania topline results now expected in the fourth quarter of 2026, ahead of previous 1H 2027 guidance. Pipeline programs, including RAP-219 long-acting injectable formulation, RAP-219 in primary generalized tonic-clonic seizures, and <ALPHA>6<BETA>4 nAChR in chronic pain and migraine, continue to advance. Strategic collaboration and license agreement entered into with Tenacia Biotechnology to develop and commercialize RAP-219 in Greater China across indications. \"We entered 2026 with strong momentum across the RAP-219 development program, highlighted by compelling new follow-up Phase 2a data recently presented at AAN that further reinforces RAP-219's treatment effect in focal onset seizures and builds confidence as we enter our Phase 3 trials,\" said Abraham N. Cees","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4178","BK4181","BK4218","AAN","BK4007","PK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633251929","title":"Press Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633251929","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633251929?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:01","pubTimestamp":1778011260,"startTime":"0","endTime":"0","summary":"Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A. Claseprubart granted Orphan Drug Designation by FDA for Myasthenia Gravis. Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W and 300mg/2mL Q4W in generalized Myasthenia Gravis  on track to initiate in mid-2026; top-line results anticipated in 2H'28. Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy  ongoing; top-line results on track for Q4'26. Building a rheumatology franchise around DNTH212 with first three priority indications of Sjgren's Disease , Systemic Lupus Erythematosus , and Dermatomyositis . Further strengthened the balance sheet with approximately $719 million in gross proceeds from an underwritten public offering of common stock and pre-funded warrants. Approximately $1.2 billion of cash as of March 31, 2026 provides expected runway into 2030. NEW YORK and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","DNTH","SLE","DM","AAN","LENZ","BK4007","BK4178","BK4546","BK4139","BK4161","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631631886","title":"Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2631631886","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631631886?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:25","pubTimestamp":1777548300,"startTime":"0","endTime":"0","summary":"Highlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the planned Phase 3 program for ATH434 in MSAAdvancing ATH434 toward pivotal Phase 3 program; on track for En","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284716/0/en/Alterity-Therapeutics-Releases-Appendix-4C-Q3-FY26-Quarterly-Cash-Flow-Report-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMC","IE00BKVL7J92.USD","LU0728928796.USD","LENZ","BK4143","LU2237443382.USD","ATHE","LU2746668974.SGD","LU0154245756.USD","BK4178","LU2237443549.SGD","LU0971096721.USD","LU2237443622.USD","LU0149725797.USD","LABU","AAN","IE00B1BXHZ80.USD","MSA","LU0154245673.USD","LU1923622291.USD","LU0053671581.USD","IE00BFXG1179.USD","KOL","BK4006","LU0267386448.USD","LU2237443978.SGD","BK4539","LU0757428866.USD","BK4139","IE00BZ1G4Q59.USD","LU1815336091.USD","LU2125909759.SGD","LU2237443465.HKD","LU2211815571.USD","LU2746668461.USD","BK4007","IE00BHPRN162.USD","LU2125909916.SGD","LU2237443895.HKD","BK4585","BK4588","LU0882574139.USD","LU0170899867.USD","LU1363072403.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629727041","title":"Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629727041","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629727041?lang=en_us&edition=fundamental","pubTime":"2026-04-22 21:00","pubTimestamp":1776862800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April  22, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today anno","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/22/3279030/0/en/Capricor-Therapeutics-Announces-Late-Breaking-Presentation-of-HOPE-3-Phase-3-Results-at-the-American-Academy-of-Neurology-2026-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4117","HOPE","BK4211","AAN","EMA","AFG","BK4139","BK4107","CAPR","ATMP","BK4178","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629374043","title":"Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology","url":"https://stock-news.laohu8.com/highlight/detail?id=2629374043","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629374043?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:25","pubTimestamp":1776857100,"startTime":"0","endTime":"0","summary":"-ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with previous","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/22/3278839/0/en/Alterity-Therapeutics-Presents-New-Analysis-of-ATH434-Phase-2-Trial-Data-in-Late-Breaking-Science-Session-of-the-American-Academy-of-Neurology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1815336091.USD","LU0757428866.USD","BK4007","LU1923622291.USD","LU2211815571.USD","LU0154245673.USD","MSA","BK4117","ATHE","AAN","BK4143","BK4107","BK4539","BK4178","LU2125909759.SGD","AFG","LU0728928796.USD","LENZ","LU2125909916.SGD","LU0053671581.USD","LU0154245756.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629066707","title":"Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629066707","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629066707?lang=en_us&edition=fundamental","pubTime":"2026-04-22 06:45","pubTimestamp":1776811500,"startTime":"0","endTime":"0","summary":"Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS D","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/21/3278588/0/en/Kyverna-Presents-Registrational-Trial-Primary-Analysis-for-Miv-cel-in-Stiff-Person-Syndrome-Demonstrating-Statistically-Significant-Durable-Clinical-Benefit-Across-All-Endpoints-in.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629058818","title":"Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2629058818","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629058818?lang=en_us&edition=fundamental","pubTime":"2026-04-21 22:30","pubTimestamp":1776781800,"startTime":"0","endTime":"0","summary":"As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential best-in-class efficacy and convenience in gMG U.S. regulat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/21/3278163/0/en/Cemdisiran-Dosed-Subcutaneously-Every-12-Weeks-Demonstrates-Rapid-Deep-and-Sustained-Disease-Control-in-Generalized-Myasthenia-Gravis-gMG-Phase-3-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434583.USD","IE00B19Z4B17.USD","MG","BK4585","LU0882574055.USD","LU0823416689.USD","LU1974910355.USD","VHT","REGN","LU0053666078.USD","LU0058720904.USD","LU1917777945.USD","BK4178","LU2023250504.SGD","BK4123","LU0114720955.EUR","AAN","LU2362541273.HKD","IE0031619046.USD","LU2089984988.USD","LU2468319806.SGD","LU2362540622.SGD","LU2106854487.HKD","IE00B66KJ199.SGD","LU0109394709.USD","BK4550","BK4588","IXJ","LU2362541513.USD","LU0889565916.HKD","BK4139","LU0289739699.SGD","LU0823434740.USD","IE00B7SZL793.SGD","LU0320765992.SGD","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628728598","title":"Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2628728598","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628728598?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:00","pubTimestamp":1776686400,"startTime":"0","endTime":"0","summary":"100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial Totality of efficacy and safety data reinforces miv-cel’s diff","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/20/3276926/0/en/Kyverna-Presents-Longer-Term-Phase-2-Data-for-Miv-cel-in-Generalized-Myasthenia-Gravis-at-AAN-Demonstrating-Deep-Durable-Responses-through-52-Weeks.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628728567","title":"Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®","url":"https://stock-news.laohu8.com/highlight/detail?id=2628728567","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628728567?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:00","pubTimestamp":1776686400,"startTime":"0","endTime":"0","summary":"Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of CREXONT across all prior treatment groupsDemonstrated substantial increases in daily “Good On” time, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/20/3276937/0/en/Amneal-Announces-Additional-Positive-Interim-Phase-4-ELEVATE-PD-Results-with-CREXONT-for-Parkinson-s-Disease-Including-Over-3-More-Hours-of-Daily-Good-On-Time-When-Switching-from-R.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","BK4135","CNS","AAN","LU1169589451.USD","PD","BK4116","BK4023","CD","BK4178"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628983744","title":"Argenx Showcases Broad VYVGART and Pipeline Gains at AAN 2026 to Bolster Neuromuscular Leadership","url":"https://stock-news.laohu8.com/highlight/detail?id=2628983744","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628983744?lang=en_us&edition=fundamental","pubTime":"2026-04-20 18:30","pubTimestamp":1776681008,"startTime":"0","endTime":"0","summary":"Argenx Se ( ($ARGX) ) has shared an announcement. On April 18, 2026, argenx presented new data at the American Academy of Neurology meeting in Chic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/argenx-showcases-broad-vyvgart-and-pipeline-gains-at-aan-2026-to-bolster-neuromuscular-leadership?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/argenx-showcases-broad-vyvgart-and-pipeline-gains-at-aan-2026-to-bolster-neuromuscular-leadership?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AAN","BK4178"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628079159","title":"Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2628079159","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628079159?lang=en_us&edition=fundamental","pubTime":"2026-04-20 07:00","pubTimestamp":1776639600,"startTime":"0","endTime":"0","summary":"WILMETTE, Ill., April  19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/19/3276675/0/en/Monopar-Presents-Phase-3-Data-Showing-Greater-Neurologic-Benefit-with-ALXN1840-vs-SoC-in-Wilson-Disease-Patients-with-Neurologic-Symptoms-at-AAN-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861220033.SGD","IE00BZ199S13.USD","LU1854104046.USD","BK4605","LU1978683503.SGD","ON","AAN","BK4178","LU2360107325.USD","BK4588","LU1548497426.USD","BK4512","IE00BD6J9T35.USD","BK4141","LU0124384867.USD","LU2298322129.HKD","LU1854103824.USD","LU0348723411.USD","LU0724618433.USD","LU1720051108.HKD","LU1861215975.USD","LU2357305700.SGD","IE00BFMHRM44.USD","LU1861214812.USD","LU1861219969.SGD","BK4585","LU1720051017.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628799186","title":"Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2628799186","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628799186?lang=en_us&edition=fundamental","pubTime":"2026-04-20 06:00","pubTimestamp":1776636000,"startTime":"0","endTime":"0","summary":"Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time pointsX-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in monthl","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/19/3276673/33485/en/Xenon-Presents-Azetukalner-Phase-3-X-TOLE2-Study-Results-and-48-Month-Long-term-Data-in-Focal-Onset-Seizures-at-2026-AAN-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4178","BK4585","LU0368265418.SGD","MPC","BK4023","LU0456854461.SGD","LU0300736062.USD","LU0300736492.USD","DBP","LU0266512473.USD","BK4138","HCP","LU0266512127.USD","AAN","IE00BSNM7G36.USD","LU0170899867.USD","BK4588","LU0122376428.USD","LU0788109394.HKD","SOCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628479823","title":"Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2628479823","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628479823?lang=en_us&edition=fundamental","pubTime":"2026-04-20 01:29","pubTimestamp":1776619740,"startTime":"0","endTime":"0","summary":"The one-year INFUSE study observed patient-reported migraine-related cognitive symptoms at baseline and changes over 6 months in those with at least one prior anti-calcitonin gene-related peptide  treatment failure. VALBY, Denmark, April 20, 2026 /PRNewswire/ -- H. Lundbeck A/S  today presentednew real-world 6-month results from the INFUSE study at the American Academy of Neurology  2026 Annual Meeting, underscoring the importance of evaluating the broad burden of migraine beyond headache and migraine frequency. Despite being among the most frequently reported symptoms by people living with migraine, cognition and brain fog have rarely been systematically studied. These patient-reported outcomes data highlight the opportunity to focus on elements of migraine burden that are meaningful to individuals living with migraine and report improvement of migraine-related cognitive symptoms after eptinezumab treatment.[1]. \"These real-world, patient-reported INFUSE data give greater insight into","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/lundbeck-presents-new-data-at-aan-2026-highlighting-real-world-changes-in-migraine-related-cognitive-symptoms-after-starting-vyepti-eptinezumab-302746650.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YLD","BK4178","MMD","BK4201","AAN","EC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628739121","title":"argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP","url":"https://stock-news.laohu8.com/highlight/detail?id=2628739121","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628739121?lang=en_us&edition=fundamental","pubTime":"2026-04-18 13:00","pubTimestamp":1776488400,"startTime":"0","endTime":"0","summary":"ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient populationADAPT SERON, OC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/18/3276554/0/en/argenx-Brings-Neuromuscular-Leadership-to-AAN-2026-with-New-Data-Supporting-Broader-VYVGART-Use-Across-MG-and-CIDP.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2346227817.USD","BK4208","LU1894683264.USD","LU0553294199.USD","LU0661504455.SGD","BK4178","PRO","LU1894683348.USD","IE0031619046.USD","IE00B7SZL793.SGD","LU0545039389.USD","MG","SMA","LU0738911758.USD","AAN","LU1003077747.HKD","BK4217","LU0949170772.SGD","IE00B66KJ199.SGD","LU2637428348.USD","BK4585","BK4123","BK4023","LU2500361329.USD","CMS","IE00B19Z4B17.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628052572","title":"Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2628052572","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628052572?lang=en_us&edition=fundamental","pubTime":"2026-04-17 20:00","pubTimestamp":1776427200,"startTime":"0","endTime":"0","summary":"Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP New data on spasticity further val","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/17/3276105/0/en/Lexicon-to-Present-Data-at-the-American-Academy-of-Neurology-AAN-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4531","BK4588","BK4117","HCM","BK4178","AAN","BK4007","BK4107","AFG","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627725006","title":"Alterity to Spotlight ATH434 MSA Data in Late-Breaker at AAN Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2627725006","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627725006?lang=en_us&edition=fundamental","pubTime":"2026-04-16 10:42","pubTimestamp":1776307336,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics ( ($AU:ATH) ) has shared an announcement. Alterity Therapeutics said its chief medical advisor, Vanderbilt neurologist Daniel...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alterity-to-spotlight-ath434-msa-data-in-late-breaker-at-aan-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alterity-to-spotlight-ath434-msa-data-in-late-breaker-at-aan-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4143","LU2211815571.USD","LU1815336091.USD","BK4178","LU1923622291.USD","LU2125909916.SGD","LU0154245756.USD","LU0757428866.USD","AAN","LU0053671581.USD","MSA","LU0728928796.USD","LU0154245673.USD","LU2125909759.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}]}}